<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11852">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00539006</url>
  </required_header>
  <id_info>
    <org_study_id>FFU105924</org_study_id>
    <nct_id>NCT00539006</nct_id>
  </id_info>
  <brief_title>Comparator Study Evaluating Patient Preference Of FFNS vs. FPNS</brief_title>
  <official_title>R, DB, PC, AC, One-Week, Cross-Over, MC Study to Evaluate the Efficacy and Patient Preference of Nasal Spray Characteristics of Once-Daily, Intranasal Administration of 110mcg FFNS and 200mcg FPNS in Adult Subjects With SAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this replicate study to FFU105927 is to provide data on subject preference of
      FFNS as compared with FPNS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Randomized, Double-Blind, Placebo-Controlled, Active Comparator, One-Week, Cross-Over,
      Multicenter Study to Evaluate the Efficacy, Patient Preference and Experience of One-Daily,
      Intranasal Administration of 110mcg Fluticasone Furoate Nasal Spray and 200mcg Fluticasone
      Propionate Nasal Spray in Adult Subjects with Seasonal Allergic Rhinitis (FFU105924)
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">November 2007</completion_date>
  <primary_completion_date type="Actual">November 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos</measure>
    <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor</measure>
    <time_frame>End of Crossover Period (Day 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat</measure>
    <time_frame>End of Crossover Period (Day 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use</measure>
    <time_frame>End of Crossover Period (Day 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants assessed preference over ease of use for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist</measure>
    <time_frame>End of Crossover Period (Day 22)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Participants assessed preference over gentleness of mist for the nasal sprays used during the 2 treatment periods</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos</measure>
    <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos</measure>
    <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">377</enrollment>
  <condition>Rhinitis, Allergic, Perennial</condition>
  <condition>Seasonal Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>FFNS, FPNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FPNS, FFNS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo FFNS, placebo FPNS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo FPNS, placebo FFNS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FPNS</intervention_name>
    <description>fluticasone propionate nasal spray</description>
    <arm_group_label>FPNS, FFNS</arm_group_label>
    <arm_group_label>FFNS, FPNS</arm_group_label>
    <other_name>fluticasone propionate</other_name>
    <other_name>fluticasone furoate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FFNS</intervention_name>
    <description>fluticasone furoate nasal spray</description>
    <arm_group_label>FPNS, FFNS</arm_group_label>
    <arm_group_label>FFNS, FPNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo FPNS</intervention_name>
    <description>placebo nasal spray matching fluticasone propionate nasal spray</description>
    <arm_group_label>placebo FPNS, placebo FFNS</arm_group_label>
    <arm_group_label>placebo FFNS, placebo FPNS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo FFNS</intervention_name>
    <description>placebo nasal spray matching fluticasone furoate nasal spray</description>
    <arm_group_label>placebo FPNS, placebo FFNS</arm_group_label>
    <arm_group_label>placebo FFNS, placebo FPNS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Informed consent

          -  Subject has provided an appropriately signed and dated informed consent.

          -  Otherwise healthy outpatient with fall allergy

          -  Subject is treatable on an outpatient basis.

          -  Age

          -  18 years or age or older at time of Visit 2

          -  Male or eligible female

          -  Female subjects should not be enrolled if they plan to become pregnant during the
             time of study participation. A urine pregnancy test will be required of all females
             at all visits to determine if the subject is pregnant.

          -  To be eligible for entry into the study, females of childbearing potential must
             commit to the consistent and correct use of an acceptable method of birth control, as
             defined by the following:

          -  Abstinence

          -  Females of childbearing potential who are not sexually active must commit to complete
             abstinence from intercourse for two weeks before exposure to the study drug,
             throughout the clinical trial, and for a period after the trial to account for
             elimination of the drug (minimum of six days).

          -  Oral contraceptive (either combined estrogen/progestin or progestin only)

          -  Injectable progestogen

          -  Implants of levonorgestrel

          -  Percutaneous contraceptive patches

          -  Intrauterine device (IUD) or intrauterine system (IUS) with a documented failure rate
             of less than 1% per year,

          -  Male partner who is sterile (vasectomy with documentation of azoospermia) prior to
             the female subject's entry into the study and is the sole sexual partner for that
             female subject

          -  Double barrier method-condom or occlusive cap (diaphragm or cervical /vault caps)
             plus spermicide

          -  Estrogenic vaginal ring

          -  Diagnosis of SAR

          -  SAR is defined as follows:

          -  A clinical history (written or verbal) of SAR with seasonal allergy symptoms (nasal
             symptoms) during each of the last two fall allergy seasons, and

          -  A positive skin test (by prick method) to fall allergen prevalent to the geographic
             area during the conduct of the study, within 12 months prior to Visit 1 or at Visit
             1.

          -  A positive skin test is defined as a wheal 3 mm larger than the diluent control for
             prick testing.

          -  In vitro tests for specific IgE (such as RAST, PRIST) will not be allowed as a
             diagnosis of SAR.

          -  Subjects who meet the above criteria and who may also have perennial allergic
             rhinitis or vasomotor rhinitis are eligible for randomization.

          -  Adequate exposure to seasonal pollen

          -  Subject resides within a geographical region where exposure to fall seasonal allergen
             is expected to be significant during the entire study period.

          -  Subject does not plan to travel outside this area for more than 48 hours of the study
             period.

          -  Ability to comply with study procedures

          -  Subject understands and is willing, able and likely to comply with study procedures
             and restrictions.

          -  Literate

          -  Subject must be able to read, comprehend, and record information in English

        Exclusion Criteria:

          -  Recent use (less than 1 year) of using branded (FLONASE) or generic FPNS or use of
             FFNS (VERAMYST).

          -  Significant concomitant medical conditions, defined as but not limited to:

          -  A historical or current evidence of clinically significant uncontrolled disease of
             any body system (e.g., tuberculosis, psychological disorders, eczema). Significant is
             defined as any disease that, in the opinion of the investigator, would put the safety
             of the subject at risk through study participation or which would confound the
             interpretation of the study results if the disease/condition exacerbated during the
             study.

          -  A severe physical obstruction of the nose (e.g., deviated septum or nasal polyp) or
             nasal septal perforation that could affect the deposition of intranasal study drug

          -  Nasal (eg, nasal septum) injury or surgery in the last 3 months

          -  Asthma, with the exception of mild intermittent asthma [National Asthma Education and
             Prevention Program (NARPP) Guidelines, 2002].

          -  Rhinitis medicamentosa

          -  Bacterial or viral infection (e.g., common cold) of the eyes or upper respiratory
             tract within two weeks of Visit 1 or during the screening period

          -  Documented evidence of acute or significant chronic sinusitis, as determined by the
             individual investigator

          -  Current or history of glaucoma and/or cataracts or ocular herpes simplex

          -  Physical impairment that would affect subject's ability to participate safely and
             fully in the study

          -  Clinical evidence of a Candida infection of the nose

          -  History of psychiatric disease, intellectual deficiency, poor motivation, substance
             abuse (including drug and alcohol) or other conditions that will limit the validity
             of informed consent or that would confound the interpretation of the study results

          -  History of adrenal insufficiency

          -  History of shingles

          -  Chickenpox or measles: A subject is not eligible if he/she currently has chickenpox
             or measles, or has been exposed to chickenpox or measles during the last 3 weeks and
             is non-immune. If a subject develops chickenpox or measles during the study, he/she
             will be withdrawn from the study. If a non-immune subject is exposed to chickenpox or
             measles during the study, his/her continuation in the study will be at the discretion
             of the investigator, taking into consideration the likelihood of developing active
             disease.

          -  Use of other corticosteroids, defined as:

          -  Intranasal corticosteroid within four weeks prior to Visit 1.

          -  Inhaled, oral, intramuscular, intravenous, ocular, and/or dermatological
             corticosteroid (with the exception of hydrocortisone cream/ointment, 1% or less)
             within eight weeks prior to Visit 1.

          -  Use of other allergy medications within the timeframe indicated relative to Visit 1

          -  Intranasal cromolyn within 14 days prior to Visit 1

          -  Short-acting prescription and OTC antihistamines, including antihistamines contained
             in insomnia and 'nighttime' pain formulations taken for insomnia, within 3 days prior
             to Visit 1

          -  Long-acting antihistamines within 10 days prior to Visit 1: loratadine,
             desloratadine, fexofenadine, cetirizine

          -  Oral or intranasal decongestants within 3 days prior to Visit 1

          -  Intranasal, oral, or inhaled anticholinergics within 3 days prior to Visit 1

          -  Oral antileukotrienes within 3 days prior to Visit 1

          -  Subcutaneous omalizumab (Xolair) within 5 months of Visit 1

          -  Intranasal antihistamines (e.g. Astelin) within 2 weeks prior to Visit 1

          -  Use of other medications that may affect allergic rhinitis or its symptoms

          -  Chronic use of concomitant medications, such as tricyclic antidepressants, that would
             affect assessment of the effectiveness of the study drug

          -  Chronic use of long-acting beta-agonists (e.g., salmeterol)

          -  Chronic use of other intranasally administered medications (e.g., calcitonin-salmon)

          -  Nasal irrigation solutions

          -  Use of immunosuppressive medications 8 weeks prior to screening and during the study

          -  Use of any medications that significantly inhibit the cytochrome P450 subfamily
             enzyme CYP3A4, including ritonavir and ketoconazole

          -  Immunotherapy

          -  Subjects may be enrolled into the study if the immunotherapy was not initiated within
             30 days of Visit 1, if the dose has remained fixed over the 30 days prior to Visit 1,
             and the dose will remain fixed for the duration of the study.

          -  Allergy/Intolerance

          -  Known hypersensitivity to corticosteroids or any excipients in the product

          -  Clinical trial/experimental medication experience

          -  Has recent exposure to an investigational study drug within 30 days of Visit 1

          -  Participation in a previous or current GSK FFNS study

          -  Positive or inconclusive pregnancy test or female who is breastfeeding

          -  Has a positive or inconclusive pregnancy test at Visit 1 or Visit 2

          -  Affiliation with investigational site

          -  Subject is a participating investigator, sub-investigator, study co-ordinator, or
             employee of a participating investigator, or is an immediate family member of the
             aforementioned.

          -  Current tobacco use

          -  Subject currently uses smoking products including cigarettes, cigars, and pipe or
             chewing tobacco.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fresno</city>
        <state>California</state>
        <zip>93720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92647</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Andover</city>
        <state>Massachusetts</state>
        <zip>01845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brick</city>
        <state>New Jersey</state>
        <zip>8724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skillman</city>
        <state>New Jersey</state>
        <zip>08558</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14618</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsicana</city>
        <state>Texas</state>
        <zip>75110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77070</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerrville</city>
        <state>Texas</state>
        <zip>78028</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <lastchanged_date>December 15, 2011</lastchanged_date>
  <firstreceived_date>October 2, 2007</firstreceived_date>
  <firstreceived_results_date>November 14, 2008</firstreceived_results_date>
  <responsible_party>
    <name_title>Cheri Hudson; Clinical Disclosure Advisor</name_title>
    <organization>GSK Clinical Disclosure</organization>
  </responsible_party>
  <keyword>fluticasone propionate</keyword>
  <keyword>seasonal allergic rhinitis</keyword>
  <keyword>fluticasone furoate</keyword>
  <keyword>experience</keyword>
  <keyword>GW685698X</keyword>
  <keyword>preference</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic, Perennial</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluticasone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
          <description>Participants who received Fluticasone Furoate Nasal Spray (FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
        </group>
        <group group_id="P2">
          <title>Placebo - FF/FP</title>
          <description>Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.</description>
        </group>
        <group group_id="P3">
          <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
          <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS)110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
        </group>
        <group group_id="P4">
          <title>Placebo - FP/FF</title>
          <description>Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Pre-treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="95"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="95"/>
                <participants group_id="P4" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Washout</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="96"/>
                <participants group_id="P2" count="94"/>
                <participants group_id="P3" count="93"/>
                <participants group_id="P4" count="90"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="16"/>
                <participants group_id="P4" count="9"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failed to meet continuation criteria</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="14"/>
                <participants group_id="P4" count="6"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Treatment Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="84"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Post-Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="83"/>
                <participants group_id="P3" count="77"/>
                <participants group_id="P4" count="81"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
          <description>Participants who received Fluticasone Furoate Nasal Spray (FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
        </group>
        <group group_id="B2">
          <title>Placebo - FF/FP</title>
          <description>Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.</description>
        </group>
        <group group_id="B3">
          <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
          <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS)110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
        </group>
        <group group_id="B4">
          <title>Placebo - FP/FF</title>
          <description>Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="96"/>
                <measurement group_id="B2" value="95"/>
                <measurement group_id="B3" value="95"/>
                <measurement group_id="B4" value="91"/>
                <measurement group_id="B5" value="377"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.3" spread="13.89"/>
                <measurement group_id="B2" value="42" spread="12.48"/>
                <measurement group_id="B3" value="40.5" spread="12.29"/>
                <measurement group_id="B4" value="39.7" spread="14.32"/>
                <measurement group_id="B5" value="39.9" spread="13.33"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="62"/>
                <measurement group_id="B2" value="73"/>
                <measurement group_id="B3" value="67"/>
                <measurement group_id="B4" value="60"/>
                <measurement group_id="B5" value="262"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="34"/>
                <measurement group_id="B2" value="22"/>
                <measurement group_id="B3" value="28"/>
                <measurement group_id="B4" value="31"/>
                <measurement group_id="B5" value="115"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>American/African Heritage</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="8"/>
                <measurement group_id="B3" value="10"/>
                <measurement group_id="B4" value="8"/>
                <measurement group_id="B5" value="34"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>American Indian or Alaska Native</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="5"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Native Hawaiian or other Pacific Islander</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="0"/>
                <measurement group_id="B5" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="88"/>
                <measurement group_id="B2" value="84"/>
                <measurement group_id="B3" value="82"/>
                <measurement group_id="B4" value="80"/>
                <measurement group_id="B5" value="334"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American/African-American Indian/Alaskan</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="1"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>African American/African Heritage &amp; White</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="1"/>
                <measurement group_id="B4" value="1"/>
                <measurement group_id="B5" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Secondary</type>
        <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat</title>
        <description>Participants assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
        <time_frame>End of Crossover Period (Day 22)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population. These measures are from the product preference questionnaire given at the end of the study. Because questionnaires were comparative in nature, only subjects who completed both treatment periods were included in the analyses. In addition, there are small variations due to non-response for individual questions.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray(FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week(treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Leaking Out of Nose/Down Throat</title>
            <description>Participants assessed preference over leaking out of nose/down throat for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred - Fluticasone Furoate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="46"/>
                  <measurement group_id="O3" value="89"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred - Fluticasone Propionate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="15"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Preference</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use</title>
        <description>Participants assessed preference over ease of use for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
        <time_frame>End of Crossover Period (Day 22)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population. These measures are from the product preference questionnaire given at the end of the study. Because questionnaires were comparative in nature, only subjects who completed both treatment periods were included in the analyses. In addition, there are small variations due to non-response for individual questions.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray(FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week(treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Ease of Use</title>
            <description>Participants assessed preference over ease of use for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred - Fluticasone Furoate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19"/>
                  <measurement group_id="O2" value="28"/>
                  <measurement group_id="O3" value="47"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred - Fluticasone Propionate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="42"/>
                  <measurement group_id="O2" value="37"/>
                  <measurement group_id="O3" value="79"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Preference</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="16"/>
                  <measurement group_id="O2" value="12"/>
                  <measurement group_id="O3" value="28"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos</title>
        <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.</description>
        <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to study treatment, and was to form the basis of all summaries of background, demographic, safety, and efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray (FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - FF/FP</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS)110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FP/FF</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="93"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparison of Mean Change From Baseline in Daily Reflective Total Nasal Symptom Score (rTNSS) Over Treatment Periods of Active Drug Nasal Sprays Versus Placebos</title>
            <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12. The mean of AM and PM scores were used.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change from Baseline Treatment Period One</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.7" spread="0.29"/>
                  <measurement group_id="O2" value="-1.5" spread="0.20"/>
                  <measurement group_id="O3" value="-2.4" spread="0.24"/>
                  <measurement group_id="O4" value="-1.6" spread="0.22"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline Treatment Period Two</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.5" spread="0.29"/>
                  <measurement group_id="O2" value="-1.9" spread="0.24"/>
                  <measurement group_id="O3" value="-2.7" spread="0.27"/>
                  <measurement group_id="O4" value="-1.7" spread="0.21"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FFNS combined across treatment arms 1 &amp; 2 compared with Placebo FFNS combined across treatment arms 1 &amp; 2.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.1</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.5</ci_lower_limit>
            <ci_upper_limit>-0.6</ci_upper_limit>
            <estimate_desc>Mean Difference = Mean Change in FFNS - Mean Change in Placebo</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>FPNS combined across treatment arms 1 &amp; 2 compared with Placebo FPNS combined across treatment arms 1 &amp; 2.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>0.004</p_value>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.6</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.22</dispersion_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-1.1</ci_lower_limit>
            <ci_upper_limit>-0.2</ci_upper_limit>
            <estimate_desc>Mean Difference = Mean Change in FPNS - Mean Change in Placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor</title>
        <description>Participants assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
        <time_frame>End of Crossover Period (Day 22)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to study treatment, and was to form the basis of all summaries of background, demographic, safety, and efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray (FFNS)110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week(treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="95"/>
                  <measurement group_id="O3" value="191"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Scent/Odor</title>
            <description>Participants assessed preference of scent/odor for the nasal sprays used during the treatment periods by answering &quot;I prefer product 1&quot; for spray used during Treatment Period 1 or &quot;I prefer product 2&quot; for spray used during Treatment Period 2. Participant could also choose &quot;I have no preference.&quot;</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred - Fluticasone Furoate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="43"/>
                  <measurement group_id="O2" value="41"/>
                  <measurement group_id="O3" value="84"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred - Fluticasone Propionate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="21"/>
                  <measurement group_id="O2" value="17"/>
                  <measurement group_id="O3" value="38"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Preference</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="13"/>
                  <measurement group_id="O2" value="19"/>
                  <measurement group_id="O3" value="32"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Statistical analysis applies to FFNS and FPNS categories.</groups_desc>
            <non_inferiority>No</non_inferiority>
            <p_value>&lt;0.001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel(CMH): stratified approximation to Prescotts test; variation of chi-square test for treatment sequence/subjects no preference.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist</title>
        <description>Participants assessed preference over gentleness of mist for the nasal sprays used during the 2 treatment periods</description>
        <time_frame>End of Crossover Period (Day 22)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population. These measures are from the product preference questionnaire given at the end of the study. Because questionnaires were comparative in nature, only subjects who completed both treatment periods were included in the analyses. In addition, there are small variations due to non-response for individual questions.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray(FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week(treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O3">
            <title>Total</title>
            <description>Total of all reporting groups</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="77"/>
                  <measurement group_id="O2" value="77"/>
                  <measurement group_id="O3" value="154"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Participant Preference of Fluticasone Furoate Nasal Spray (FFNS) Versus Fluticasone Propionate Nasal Spray (FPNS) Based on Gentleness of Mist</title>
            <description>Participants assessed preference over gentleness of mist for the nasal sprays used during the 2 treatment periods</description>
            <units>Participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Preferred - Fluticasone Furoate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="37"/>
                  <measurement group_id="O2" value="49"/>
                  <measurement group_id="O3" value="86"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Preferred - Fluticasone Propionate Nasal Spray</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="17"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="31"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>No Preference</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="23"/>
                  <measurement group_id="O2" value="14"/>
                  <measurement group_id="O3" value="37"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos</title>
        <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.</description>
        <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to study treatment, and was to form the basis of all summaries of background, demographic, safety, and efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray(FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week(treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - FF/FP</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FP/FF</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="93"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparision of Mean Change From Baseline Over Treatment Periods in Daytime Reflective Total Nasal Symptom Scores (D r-TNSS) for Active Drug Nasal Sprays Versus Placebos</title>
            <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change from Baseline Treatment Period One</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.8" spread="0.30"/>
                  <measurement group_id="O2" value="-1.6" spread="0.21"/>
                  <measurement group_id="O3" value="-2.6" spread="0.26"/>
                  <measurement group_id="O4" value="-1.7" spread="0.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change from Baseline Treatment Period Two</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.6" spread="0.31"/>
                  <measurement group_id="O2" value="-2.0" spread="0.26"/>
                  <measurement group_id="O3" value="-2.8" spread="0.28"/>
                  <measurement group_id="O4" value="-1.9" spread="0.24"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos</title>
        <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.</description>
        <time_frame>Baseline, Treatment Period 1 (Days 1-7), Treatment Period 2 (Days 15-21)</time_frame>
        <safety_issue>No</safety_issue>
        <population>Intent-to-Treat (ITT) population consisted of all participants who were randomized to study treatment, and was to form the basis of all summaries of background, demographic, safety, and efficacy data.</population>
        <group_list>
          <group group_id="O1">
            <title>Fluticasone Furoate NS/Fluticasone Propionate NS</title>
            <description>Participants who received Fluticasone Furoate Nasal Spray(FFNS) 110 mcg every day (QD) followed by Fluticasone Propionate Nasal Spray (FPNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FPNS 110 mcg QD, followed by FFNS 200 mcg QD.</description>
          </group>
          <group group_id="O2">
            <title>Placebo - FF/FP</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone Furoate/Fluticasone Propionate group.</description>
          </group>
          <group group_id="O3">
            <title>Fluticasone Propionate NS/Fluticasone Furoate NS</title>
            <description>Participants who received Fluticasone Propionate Nasal Spray (FPNS) 110 mcg QD followed by Fluticasone Furoate Nasal Spray (FFNS) 200 mcg QD for one week (treatment 1), followed by a 7 day washout period, and switched to one week of treatment 2, given FFNS 110 mcg QD, followed by FPNS 200 mcg QD.</description>
          </group>
          <group group_id="O4">
            <title>Placebo - FP/FF</title>
            <description>Participants who received no active drug but believed they were following the Fluticasone propionate/Fluticasone Furoate group.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="96"/>
                  <measurement group_id="O2" value="93"/>
                  <measurement group_id="O3" value="95"/>
                  <measurement group_id="O4" value="89"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Comparision of Mean Change From Baseline Over Treatment Periods in Nighttime Reflective Total Nasal Symptom Scores (N-rTNSS) for Active Drug Nasal Sprays Versus Placebos</title>
            <description>Reflective Total Nasal Symptom scores (rTNSS) symptoms of rhinorrhea, nasal congestion, nasal itching, sneezing using scale of: 0=none, 1=mild, 2=moderate, 3=severe; maximum score=12.</description>
            <units>Scores on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Error</dispersion>
            <category_list>
              <category>
                <sub_title>Change From Baseline Treatment Period One</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.5" spread="0.29"/>
                  <measurement group_id="O2" value="-1.3" spread="0.21"/>
                  <measurement group_id="O3" value="-2.4" spread="0.26"/>
                  <measurement group_id="O4" value="-1.6" spread="0.23"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Change From Baseline Treatment Period Two</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="-2.4" spread="0.29"/>
                  <measurement group_id="O2" value="-1.9" spread="0.25"/>
                  <measurement group_id="O3" value="-2.6" spread="0.30"/>
                  <measurement group_id="O4" value="-1.6" spread="0.22"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Fluticasone Furoate Nasal Spray</title>
          <description>Subjects who received Fluticasone Furoate.</description>
        </group>
        <group group_id="E2">
          <title>Fluticason Propionate Nasal Spray</title>
          <description>Subjects who receive Fluticasone Propionate Nasal Spray.</description>
        </group>
        <group group_id="E3">
          <title>Placebo - FF</title>
          <description>Subjects who took no active drug but believed they were on Fluticasone Furoate Nasal Spray.</description>
        </group>
        <group group_id="E4">
          <title>Placebo - FP</title>
          <description>Subjects who took no active drug but believed they were on Fluticasone Propionate Nasal Spray.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="173"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="176"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="175"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>
